Neuregulin based methods for treating heart failure
View Patent ↗The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe.
1. A method for treating or delaying heart failure in a human subject in need thereof, wherein the method comprises administering to the human subject in need thereof a neuregulin 1 protein in an amount:
a) from about 0.3 μg to about 2.4 μg/kg/day;
b) from about 6 EU to about 48 EU/kg/day; or
c) from about 0.04 nmol to about 0.34 nmol/kg/day.
2. The method of claim 1 , wherein the neuregulin 1 protein is neuregulin 1 β2 isoform.
3. The method of claim 1 , wherein the neuregulin 1 protein comprises the amino acid sequence set forth in SEQ ID NO:1.
4. The method of claim 1 , wherein the neuregulin 1 protein consists of the amino acid sequence set forth in SEQ ID NO:1.
5. The method of claim 1 , wherein the neuregulin 1 protein is administered to the human subject intravenously.
6. The method of claim 1 , wherein the neuregulin 1 protein is administered to the human subject for one day or multiple days.
7. The method of claim 6 , wherein the neuregulin 1 protein is administered to the human subject for at least 10 days.
8. The method of claim 7 , wherein the neuregulin 1 protein is administered to the human subject from 10 minutes to 12 hours per day.
9. The method of claim 8 , wherein the neuregulin 1 protein is administered to the human subject 10 hours per day for 10 days.
10. The method of claim 1 , wherein the human subject has or is suspected of having heart failure.
11. The method of claim 10 , wherein the heart failure is caused by one or more ischaemic, congenital, rheumatic, idiopathic, viral or toxic factors.